NCT01439321View on ClinicalTrials.gov

Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim

CompletedOBSERVATIONAL
Enrollment

280

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Immune Thrombocytopenic Purpura
Interventions
BIOLOGICAL

Eltrombopag

Switched to Eltrombopag

BIOLOGICAL

Romiplostim

Switched to Romiplostim

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01439321 - Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim | Biotech Hunter | Biotech Hunter